



MacroGenics, Inc.
Investor Relations Department
9640 MEDICAL CENTER DRIVE
Rockville, MD 20850
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: MGNX

Last Trade:	17.33
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	-0.10 (-0.574%)
Day Range	17.12 - 17.67
52-Week Range	16.63 - 33.30
Volume	143,020

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceu... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 17, 2017

[Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017](#)

Jun 17, 2017

[MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology \(EULAR 2017\)](#)

May 3, 2017

[MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results](#)

Apr 27, 2017

[MacroGenics Announces Registered Direct Offering of Common Stock](#)

Apr 26, 2017

[MacroGenics to Present at Two Upcoming Investor Conferences in May](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 28, 2017

[Annual Report \(10-K\)](#)

Apr 4, 2017

[Proxy Statement \(DEF 14A\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)

Nov 2, 2016

[Quarterly Report \(10-Q\)](#)

Aug 3, 2016

[Quarterly Report \(10-Q\)](#)